Fetal tachyarrhythmia - Part II: Treatment
Oudijk, Martijn A; Visser, Gerard HA and Meijboom, Erik J (2004) Fetal tachyarrhythmia - Part II: Treatment. Indian Pacing and Electrophysiology Journal, 4 (4). pp. 185-194. ISSN 0972-6292
There is a more recent version of this eprint available. Click here to view it.
Full text available as:
The decision to initiate pharmacological intervention in case of fetal tachycardia depends on several factors and must be weighed against possible maternal and/or fetal adverse effects inherent to the use of antiarrhythmics. First, the seriousness of the fetal condition must be recognized. Many studies have shown that in case of fetal tachycardia, there is a significant predisposition to congestive heart failure and subsequent development of fetal hydrops and even sudden cardiac death1,2,3 Secondly, predictors of congestive heart failure have been suggested in several studies, such as the percentage of time that the tachycardia is present, the gestational age at which the tachycardia occurs4, the ventricular rate5 and the site of origin of the tachycardia. However, the sensitivity of these predictors is low and they are therefore clinically not very useful. In addition, hemodynamic compromise may occur in less than 24 - 48 hours as has been shown in the fetal lamb7 and in tachycardic fetuses8,9. On the other hand, spontaneous resolution of the tachycardia has also been described10.
Available Versions of this Item
Archive Staff Only: edit this record